U.S., Oct. 3 -- ClinicalTrials.gov registry received information related to the study (NCT07204080) titled '(TNX-1500) in Kidney Transplant Recipients' on Sept. 25.
Brief Summary: The primary objective is to investigate the safety and efficacy of TNX-1500, an FC-modified anti-CD154 mAb, in five kidney transplant recipients at 12 months.
Study Start Date: Jan. 01, 2026
Study Type: INTERVENTIONAL
Condition:
Kidney Transplant
Kidney Transplant Failure and Rejection
Immunosuppression
Immunosuppression After Kidney Transplantation
Intervention:
DRUG: TNX-1500
This is an open-label, single-center, single-arm study to assess the safety and efficacy of TNX-1500, an Fc-modified anti-DF154 mAb in five adult kidney transplant recipients.
PROC...